Literature DB >> 20049528

Disease severity in sibling pairs with type 1 Gaucher disease.

Deborah Elstein1, Ayelet Gellman, Gheona Altarescu, Aya Abrahamov, Irith Hadas-Halpern, Mici Phillips, Maya Margalit, Ehud Lebel, Menachem Itzchaki, Ari Zimran.   

Abstract

The only prognostic markers in Gaucher disease, the most common lysosomal storage disorder, are young age at first symptom/sign and the presence of null/severe mutations, both being predictive of more severe phenotypes. Therefore, it would be helpful to know whether siblings with the same genotype can be expected to experience comparable phenotypic expression. All non-neuronopathic sibling pairs in our referral clinic (1993-2008) with the same genotype were included. For each pair, gender, date of birth, severity score index at presentation, age at diagnosis and first symptom/sign, presence of bone involvement, spleen status, and use of enzyme replacement therapy were tabulated. There were 90 pairs of siblings: two sets of identical twins; 24 pairs of brothers, 24 pairs of sisters, and 42 pairs of mixed gender. For all measures of disease severity used, only in sibling pairs with an older sister and a younger brother were phenotypes significantly different between siblings. Thus, this large cohort of sibling pairs with type 1 Gaucher disease confirmed that, in general, the phenotypic expression in the younger sibling will be similar enough to that of an older affected sibling that genetic counseling may use those findings in a prognostic way.

Entities:  

Mesh:

Year:  2010        PMID: 20049528     DOI: 10.1007/s10545-009-9024-7

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  11 in total

1.  Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy.

Authors:  A Zimran; A Abrahamov; D Elstein
Journal:  Isr Med Assoc J       Date:  2000-02       Impact factor: 0.892

Review 2.  Gaucher's disease: genetic counselling and population screening.

Authors:  E Levy-Lahad; A Zimran
Journal:  Baillieres Clin Haematol       Date:  1997-12

3.  Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity.

Authors:  Phillip D Whitfield; Paul Nelson; Peter C Sharp; Colleen A Bindloss; Caroline Dean; Elaine M Ravenscroft; Beverley A Fong; Michael J Fietz; John J Hopwood; Peter J Meikle
Journal:  Mol Genet Metab       Date:  2002-01       Impact factor: 4.797

4.  Prediction of severity of Gaucher's disease by identification of mutations at DNA level.

Authors:  A Zimran; J Sorge; E Gross; M Kubitz; C West; E Beutler
Journal:  Lancet       Date:  1989-08-12       Impact factor: 79.321

5.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

6.  Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment.

Authors:  A Zimran; D Elstein; R Kannai; S Zevin; I Hadas-Halpern; E Levy-Lahad; Y Cohen; M Horowitz; A Abrahamov
Journal:  Am J Med       Date:  1994-07       Impact factor: 4.965

7.  Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease.

Authors:  D Elstein; A Abrahamov; I Hadas-Halpern; A Meyer; A Zimran
Journal:  QJM       Date:  1998-07

Review 8.  The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).

Authors:  Ari Zimran; Elizabeth Morris; Eugen Mengel; Paige Kaplan; Nadia Belmatoug; Derralynn A Hughes; Vera Malinova; Rene Heitner; Elisa Sobreira; Mirando Mrsić; Sorina Granovsky-Grisaru; Dominick Amato; Stephan vom Dahl
Journal:  Blood Cells Mol Dis       Date:  2009-06-06       Impact factor: 3.039

9.  Twin pairs showing discordance of phenotype in adult Gaucher's disease.

Authors:  R H Lachmann; I R Grant; D Halsall; T M Cox
Journal:  QJM       Date:  2004-04

10.  Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionisation tandem mass spectrometry: in utero indicators of lysosomal storage diseases.

Authors:  Steven L Ramsay; Irene Maire; Colleen Bindloss; Maria Fuller; Phillip D Whitfield; Monique Piraud; John J Hopwood; Peter J Meikle
Journal:  Mol Genet Metab       Date:  2004-11       Impact factor: 4.797

View more
  9 in total

1.  Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl.

Authors:  Jie Lu; Jeffrey Chiang; Rajiv R Iyer; Eli Thompson; Christine R Kaneski; David S Xu; Chunzhang Yang; Masako Chen; Richard J Hodes; Russell R Lonser; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

2.  Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation.

Authors:  Clarence K Zhang; Philip B Stein; Jun Liu; Zuoheng Wang; Ruhua Yang; Judy H Cho; Peter K Gregersen; Johannes M F G Aerts; Hongyu Zhao; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

3.  Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy.

Authors:  Philip Stein; Advitya Malhotra; Andrew Haims; Gregory M Pastores; Pramod K Mistry
Journal:  J Inherit Metab Dis       Date:  2010-08-04       Impact factor: 4.982

4.  A disease severity scoring system for children with type 1 Gaucher disease.

Authors:  Staci Kallish; Paige Kaplan
Journal:  Eur J Pediatr       Date:  2012-09-20       Impact factor: 3.183

5.  Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.

Authors:  Azza Abdel Gawad Tantawy; Eman Mounir Sherif; Amira Abdel Moneam Adly; Sahar Hassanine; Amina Hafez Awad
Journal:  J Inherit Metab Dis       Date:  2013-03-19       Impact factor: 4.982

6.  Association Between Progranulin and Gaucher Disease.

Authors:  Jinlong Jian; Shuai Zhao; Qing-Yun Tian; Helen Liu; Yunpeng Zhao; Wen-Chi Chen; Gabriele Grunig; Paola A Torres; Betty C Wang; Bai Zeng; Gregory Pastores; Wei Tang; Ying Sun; Gregory A Grabowski; Max Xiangtian Kong; Guilin Wang; Ying Chen; Fengxia Liang; Herman S Overkleeft; Rachel Saunders-Pullman; Gerald L Chan; Chuan-Ju Liu
Journal:  EBioMedicine       Date:  2016-08-04       Impact factor: 8.143

Review 7.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Fabrice Camou; Christine Serratrice; Roseline Froissart; Catherine Caillaud; Thierry Levade; Leonardo Astudillo; Jacques Serratrice; Anaïs Brassier; Christian Rose; Thierry Billette de Villemeur; Marc G Berger
Journal:  Int J Mol Sci       Date:  2017-02-17       Impact factor: 5.923

8.  Aortic calcification in Gaucher disease: a case report.

Authors:  Saud Alsahli; Dalal K Bubshait; Zuhair A Rahbeeni; Majid Alfadhel
Journal:  Appl Clin Genet       Date:  2018-10-17

9.  Chitinase-3-like Protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher Disease.

Authors:  Jinlong Jian; Yuehong Chen; Rossella Liberti; Wenyu Fu; Wenhuo Hu; Rachel Saunders-Pullman; Gregory M Pastores; Ying Chen; Ying Sun; Gregory A Grabowski; Chuan-Ju Liu
Journal:  EBioMedicine       Date:  2018-01-31       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.